Skip to main content
. 2017 Feb 22;13(4):2607–2614. doi: 10.3892/ol.2017.5761

Figure 7.

Figure 7.

FFJ-3 increases the ratio of Bax/Bcl-2 expression and activates the caspase-3 cascade in cancer cells. Changes in Bcl-2, Bax, caspase-3, cleaved caspase-3, PARP and cleaved PARP expression were examined in HepG2, A549 and MCF-7 cells following FFJ-3 treatment for 48 h. (A) Western blot analysis of Bax and Bcl-2 protein expression following treatment with FFJ-3. (B) FFJ-3 significantly increased the ratio of Bax/Bcl-2 protein expression. (C) Western blot analysis of caspase-3, cleaved caspase-3, PARP and cleaved PARP protein expression following treatment with FFJ-3. (D) FFJ-3 activates the caspase-3 cascade in cancer cells. *P<0.05, **P<0.01 compared with the untreated control group. Bcl-2, B-cell lymphoma 2; Bax, Bcl-2 associated X apoptosis regulator; PARP, poly (ADP-ribose) polymerase; MFI, mean fluorescence intensity.